Stock Price Quote

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE1094.15-31.25 (-2.78 %)
PREV CLOSE ( ) 1125.40
OPEN PRICE ( ) 1069.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 150893
TODAY'S LOW / HIGH ( )1060.50 1170.00
52 WK LOW / HIGH ( )701.4 1309
NSE1094.20-31.4 (-2.79 %)
PREV CLOSE( ) 1125.60
OPEN PRICE ( ) 1060.50
BID PRICE (QTY) 1094.20 (2)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6466031
TODAY'S LOW / HIGH( ) 1060.00 1174.40
52 WK LOW / HIGH ( )701.8 1309.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1978
Management Info
Shyam S Bhartia - Chairman Priyavrat Bhartia - Managing Director
Registered Office

Address Bhartiagram ,Jyotiba Phoolay Nagar, ,
Gajraula,
Uttar Pradesh-244223

Phone 05924-267437

Email invstors@jubl.com

Website www.jubilantpharmova.com

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
Listing : BSE, NSE

NEWS

13Jun Jubilant Pharmova gets nod to sell, tr
Jubilant Pharmova has received approval for sale and transfer of the act..
20Mar Jubilant Pharmova’s arm inks Sharehold
Jubilant Pharmova’s step down subsidiary -- Jubilant Biosys Innovative R..
13Mar Jubilant Pharmova's arm gets EIR with
Jubilant Pharmova’s subsidiary -- Jubilant Cadista Pharmaceuticals Inc.,..
13Mar Jubilant Pharmova trades higher on the
Jubilant Pharmova is currently trading at Rs. 867.05, up by 1.80 points..
27Jan Jubilant Pharmova’s arm voluntary pays
Jubilant Pharmova’s step down subsidiary -- Jubilant Pharma Holdings Inc..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit136192
Gross Profit 235 376
Operating Profit 4391317
Net Sales 21737457

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  10524.65 (3.40%)
M.Cap ( in Cr)26311.63
RPG Life Sciences (BSE)
peergroup  2339.50 (4.07%)
M.Cap ( in Cr)3869.30
Abbott India (BSE)
peergroup  31545.15 (0.22%)
M.Cap ( in Cr)67031.24
Concord Biotech (BSE)
peergroup  2110.55 (2.44%)
M.Cap ( in Cr)22079.77
Onesource Specialty (BSE)
peergroup  2024.35 (2.45%)
M.Cap ( in Cr)23171.93

Shareholding Pattern

PROMOTERS 50.68%
MUTUAL FUNDS/UTI 3.66%
NON-INSTITUTION 25.06%
FI/BANKS/INSURANCE 1.36%
GOVERNMENT 0%
FII 0%

About Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd. was incorporated in the year 1978. Its today's share price is 1094.15. Its current market capitalisation stands at Rs 17427.75 Cr. In the latest quarter, company has reported Gross Sales of Rs. 7847 Cr and Total Income of Rs.8881 Cr. The company's management includes Ramakrishnan Arul, Naresh Kapoor, Shivpriya Nanda, Harsh Mahajan, Shirish G Belapure, Arun Seth, Vivek Mehra, Sushil Kumar Roongta, Arvind Chokhany, Arjun Shanker Bhartia, Priyavrat Bhartia, Hari S Bhartia, Shyam S Bhartia.

It is listed on the BSE with a BSE Code of 530019 , NSE with an NSE Symbol of JUBLPHARMA and ISIN of INE700A01033. It's Registered office is at Bhartiagram ,Jyotiba Phoolay Nagar, Gajraula-244223, Uttar Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, KN Gutgutia & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.